Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11931623rdf:typepubmed:Citationlld:pubmed
pubmed-article:11931623lifeskim:mentionsumls-concept:C0033262lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C0024337lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:11931623lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:11931623pubmed:issue8lld:pubmed
pubmed-article:11931623pubmed:dateCreated2002-4-4lld:pubmed
pubmed-article:11931623pubmed:abstractTextThe 5-tetrazole amide of L-N(6)-(1-iminoethyl)lysine (L-NIL), L-N(6)-(1-iminoethyl)lysine 5-tetrazole amide (1), has been prepared and evaluated. In contrast to L-NIL, 1 is a stable, nonhygroscopic, crystalline solid. Unlike L-NIL, 1 has minimal inhibitory activity in vitro on human inducible nitric oxide synthase (iNOS). However, it is rapidly converted in vivo to L-NIL and produces dose-dependent inhibition of iNOS in acute and chronic models of inflammation in the rodent with efficacy comparable to L-NIL. In addition, both 1 and L-NIL exhibit significant and comparable in vivo selectivity for the inhibition of iNOS vs endothelial NOS. Doses approximately 80-fold greater than those that inhibited inflammation do not elevate systemic blood pressure. In summary, both the physical properties and the pharmacological profile of 1 make it an ideal molecule for preclinical and clinical studies on the role of selective iNOS inhibitors in mediating inflammatory disease processes.lld:pubmed
pubmed-article:11931623pubmed:languageenglld:pubmed
pubmed-article:11931623pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:citationSubsetIMlld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11931623pubmed:statusMEDLINElld:pubmed
pubmed-article:11931623pubmed:monthAprlld:pubmed
pubmed-article:11931623pubmed:issn0022-2623lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:ManningPamela...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:ConnorJane...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:ZhangYanYlld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:HallinanE...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:TsymbalovSofy...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:DornClifford...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:PitzeleBarnet...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:HansenDonald...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:MooreWilliam...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:JeromeGina...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:BransonLinda...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:WidomskiDebor...lld:pubmed
pubmed-article:11931623pubmed:authorpubmed-author:CurrieMark...lld:pubmed
pubmed-article:11931623pubmed:issnTypePrintlld:pubmed
pubmed-article:11931623pubmed:day11lld:pubmed
pubmed-article:11931623pubmed:volume45lld:pubmed
pubmed-article:11931623pubmed:ownerNLMlld:pubmed
pubmed-article:11931623pubmed:authorsCompleteYlld:pubmed
pubmed-article:11931623pubmed:pagination1686-9lld:pubmed
pubmed-article:11931623pubmed:dateRevised2011-10-27lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:meshHeadingpubmed-meshheading:11931623...lld:pubmed
pubmed-article:11931623pubmed:year2002lld:pubmed
pubmed-article:11931623pubmed:articleTitleSynthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor.lld:pubmed
pubmed-article:11931623pubmed:affiliationDepartment of Arthritis and Inflammation Pharmacology, Pharmacia Corporation, 4901 Searle Parkway, Skokie, Illinois 60077, USA. ann.hallinan@pharmacia.comlld:pubmed
pubmed-article:11931623pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11931623lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11931623lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11931623lld:pubmed